Latest Research Study on Dyspepsia Drugs Market
Global Dyspepsia Drugs Market reached at a CAGR during the forecast period 2024-2031.
A Dyspepsia Drug refers to medication used to treat dyspepsia, which is a general term for indigestion or discomfort in the upper abdomen. Dyspepsia is commonly characterized by symptoms such as bloating, heartburn, nausea, and early fullness during meals. These drugs help relieve symptoms by neutralizing stomach acid, improving gastric motility, or reducing inflammation in the digestive tract
Dyspepsia, or indigestion, affects a large portion of the global population and can result from a variety of factors, including dietary habits, stress, and underlying conditions like gastritis or gastroesophageal reflux disease (GERD). Dyspepsia drugs are typically divided into several categories, including antacids, H2 blockers, proton pump inhibitors (PPIs), and prokinetic agents, each targeting different aspects of the digestive process.
The increasing prevalence of digestive disorders, coupled with growing awareness about treatment options, is driving the demand for dyspepsia drugs. These medications offer relief by regulating stomach acid levels, promoting better digestion, and easing discomfort. With the rise in lifestyle-related digestive issues, the market for dyspepsia drugs continues to grow, providing patients with a variety of treatment options for managing indigestion and its related symptoms.
Download Free Sample PDF: https://www.datamintelligence.com/download-sample/dyspepsia-drugs-market
Market Growth Drivers:
The increasing preference for OTC drugs for dyspepsia treatment
Over-the-counter (OTC) dyspepsia drugs are non-prescription medications commonly found in pharmacies and retail outlets, designed to ease symptoms of dyspepsia, including abdominal discomfort and bloating. The growing popularity of these OTC treatments has spurred increased activity in the pharmaceutical industry.
Proton pump inhibitors (PPIs) are the most widely used drugs to manage dyspepsia. For instance, according to Drug Watch 2023, PPIs are among the most frequently prescribed medications worldwide, with nearly 15 million people in the U.S. using them annually.
Additionally, many pharmaceutical companies are expanding their OTC dyspepsia drug offerings. In January 2022, Glenmark USA acquired ANDAS, gaining four OTC drugs, including famotidine, cetirizine, lansoprazole, and hydrochloride, all used to treat indigestion, heartburn, acid reflux, and allergies. This trend highlights the growing demand for accessible treatments to manage digestive discomfort.
Market Segments:
- By Disease Type: Functional Dyspepsia, Organic Dyspepsia
- By Drug Type: Proton Pump Inhibitors, Omeprazole, Esomeprazole, H-2-receptor AntagonistsCimetidine, Famotidine, Nizatidine, AntacidsCalcium Carbonate, Loperamide, Simethicone, Sodium Bicarbonate, AntibioticsAmoxicillin, Clarithromycin, Metronidazole, Tetracycline, ProkineticsBethanechol, Metoclopramide, Antidepressants
- By Route of Administration: Oral, Parenteral
- By Mode: Over the Counter, Prescription
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
- By Region: North America, Latin America, Europe, Asia Pacific, Middle East and Africa
Top Key Players:
- Takeda Pharmaceutical Company Limited.
- Sanofi
- Haleon plc.
- Procter & Gamble
- Abbott
- Pfizer Inc.
- Woodward Pharma Services LLC
- Lannett Company, Inc.
- ANI Pharmaceuticals, Inc.
- Salix Pharmaceuticals, Inc
Customize Your Scope: https://www.datamintelligence.com/customize/dyspepsia-drugs-market
Regional Growth
North America accounted for approximately 37.4% of the market share in 2022
North America is expected to maintain a dominant market share of around 37.4% throughout the forecast period, driven by factors such as increasing product approvals, the growing geriatric population, strategic collaborations with key players, and more.
For example, in March 2023, Marksans Pharma Ltd received final approval from the U.S. Food and Drug Administration (FDA) for its generic version of Famotidine tablets, commonly used to treat acid indigestion and heartburn. The FDA approved the abbreviated new drug application (ANDA) for Famotidine tablets in 10 mg and 20 mg strengths for over-the-counter (OTC) use, further expanding access to this essential treatment.
The growing geriatric population in the U.S. is a key driver of the market. Dyspepsia is more prevalent in the elderly due to a decrease in the production of essential digestive juices like bile, saliva, gastric juices, and enzymes. For instance, the 2023 United States Census Bureau report states that 55.8 million people aged 65 and above, making up 16.8% of the population, are contributing to the rising demand for treatments.
Key Development
In January 2023, metaMe Health, Inc., a leading prescription digital therapeutics (PDT) company, secured a licensing agreement for a gut-directed hypnotherapy protocol aimed at treating functional dyspepsia—a chronic condition affecting the upper gastrointestinal tract, for which effective treatment options are limited.
